Entity
Description
  • Value proposition

    Ligandal is developing precision molecular therapeutics and targeted delivery technologies.

    Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies.

    Given that increasingly complex disease states require precise and custom-tailored medicine, much of our technology development has focused on combining gene therapy with targeting peptides to enable completely new paradigms in evolutionary medicine. Currently, we are utilizing a peptide nanoscaffold based approach for treating COVID-19 without a gene therapy component, with the goal of creating a combined antidote-vaccine. My expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. At Ligandal, we have demonstrated peptide-based delivery of CRISPR, RNA, DNA, siRNA, and a range of genes or proteins to virtually any cell type.


    covid19, SARS-CoV-2 coronavirus, Coronavirus , immunoengineering, complex disease , and pharma

Corporate interactions BETA
Corporate TypeTweets Articles
Crunchbase
Crunchbase
Media, Software Development
Crunchbase
Media, Software Development
Other

10 Feb 2018


Plug and Play Tech Center
Plug and Play Tech Center
Startup accelerator & VC, Venture Capital and Private Equity Principals
Plug and Play Tech Center
Startup accelerator & VC, Venture Capital and Private Equity Principals
Other

8 Oct 2016


Similar entities
Loading...
Loading...
Social network dynamics